What are the best treatments for Castleman disease?

Treatment for Castleman disease is highly personalized and depends on whether the condition is unicentric (affecting a single lymph node region) or multicentric (affecting multiple regions). While surgical excision is the gold standard for unicentric Castleman disease, multicentric forms typically require systemic therapy, such as monoclonal antibodies or immunosuppressants, to manage systemic inflammation.

What are the first-line treatments for Castleman disease?

For unicentric Castleman disease, complete surgical resection of the affected lymph node is often curative. In contrast, multicentric Castleman disease—particularly the idiopathic form (iMCD)—requires a systemic approach. Current guidelines often prioritize IL-6 blockade, which targets the inflammatory pathways driving the disease process.

Which medications are commonly prescribed?

Physicians select therapies based on the specific subtype and severity of the patient's condition. Common pharmacological interventions include:

• Siltuximab (Sylvant): An FDA-approved monoclonal antibody that binds to interleukin-6 (IL-6), the primary driver of inflammation in many cases.


• Tocilizumab (Actemra): An IL-6 receptor antagonist used off-label when Siltuximab is not available or appropriate.


• Corticosteroids: Often used to rapidly reduce acute inflammation and symptom burden.


• Chemotherapeutic agents: Drugs such as rituximab or etoposide may be utilized in severe, refractory cases of multicentric Castleman disease.

Which specialists should be on the care team?

Managing Castleman disease requires a multidisciplinary approach due to its systemic nature. Your care team should ideally include a hematologist-oncologist, an immunologist, a pathologist (to confirm the subtype via biopsy), and a rheumatologist. The 59 members of the DiseaseMaps.org community often emphasize the importance of coordinating care between these specialists to ensure a holistic treatment plan.

How does treatment effectiveness vary?

Treatment success is highly variable because Castleman disease is not a single entity but a group of disorders. Patients with the human herpesvirus-8 (HHV-8) associated form respond differently to those with idiopathic multicentric disease. Monitoring biomarkers like C-reactive protein (CRP) and clinical symptoms is essential for assessing whether a treatment is effectively controlling the disease.

Next steps

• Consult a hematologist-oncologist specializing in lymphoproliferative disorders.


• Request a pathology review at a center of excellence to confirm your specific subtype.


• Join the DiseaseMaps community to connect with others sharing their experiences.


• Discuss current clinical trials for novel IL-6 or JAK inhibitors with your medical team.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your primary care physician or specialist for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Castleman Disease.


• Orphanet: Multicentric Castleman Disease.


• Castleman Disease Collaborative Network (CDCN): Patient Resources and Treatment Guidelines.


• PubMed: Diagnostic and treatment guidelines for idiopathic multicentric Castleman disease.